GlassScriptPhysician profile
Jenika Jade Errato
NPI 1790314524
$2,601.46
in general payments reported to CMS, 2019-2025
31 companies · $164 in 2025
The $164 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $469 · 2022: $818 · 2023: $834 · 2024: $316 · 2025: $164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,314.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,314.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $264.08 | 2021-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $240.54 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $223.76 | 2021-2023 | |
| Otsuka America Pharmaceutical, INC. | $206.31 | 2021-2025 | Rexulti, Nuedexta |
| Glaxosmithkline, LLC. | $202.23 | 2022-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $151.56 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $142.58 | 2022-2025 | Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $141.06 | 2023 | |
| Abbott Laboratories | $107.44 | 2021-2024 | Freestyle Libre |
| Axsome Therapeutics, INC. | $97.63 | 2023-2024 | Sunosi, Auvelity |
| Amarin Pharma, INC. | $71.57 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $69.80 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $66.65 | 2022-2023 | Quviviq |
| Shield Therapeutics INC | $64.40 | 2023 | Accrufer |
| Kowa Pharmaceuticals America, INC. | $59.17 | 2023 | Seglentis, Livalo |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $50.18 | 2022-2025 | Sublocade |
| Bayer Healthcare Pharmaceuticals INC. | $45.85 | 2022 | |
| Exact Sciences Corporation | $44.92 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $44.44 | 2023 | |
| Corium, LLC | $43.94 | 2024 | Azstarys |
| Vanda Pharmaceuticals INC. | $43.81 | 2023 | Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $40.65 | 2021 | |
| Jazz Pharmaceuticals INC. | $35.48 | 2022 | |
| Lundbeck LLC | $26.81 | 2024 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $22.71 | 2021 | |
| Cvrx, INC. | $20.34 | 2024 | Barostim Neo System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.61 | 2022 | |
| Esperion Therapeutics, INC. | $16.21 | 2021 | |
| Merck Sharp & Dohme LLC | $14.20 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.09 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenika Errato listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.